Unicycive Therapeutics, Inc.

Listed Company

UNCYCIK 0001766140NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-26.55M

Total Assets

$49.13M

Equity

$30.20M

Shares Out

25.24M

Op. Cash Flow

$-31.32M

Business

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address unmet medical needs with an initial emphasis on kidney disease. It develops two lead product candidates: Oxylanthanum Carbonate, an oral nanoparticle-based phosphate binder for hyperphosphatemia in dialysis patients, and UNI-494, a prodrug of nicorandil for acute kidney injury and delayed graft function. Its business model centers on in‑licensing assets, clinical development, regulatory filings, and selective commercialization or partnering. The company targets U.S. approval and commercialization while pursuing licensing and distribution partnerships in international markets and relies on contract manufacturers and regional licensees for supply and market access.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	9	20	13	12	6
General and administrative	20	12	9	7	3
Total operating expenses	30	32	21	19	9
Loss from operations	−30	−32	−21	−18	−9
Interest income	1	1	615,000	—	—
Interest expense	−71,000	−71,000	−82,000	—	—
Change in fair value of warrant liability	2	−6	−10	—	—
Total other income (expenses)	3	−5	−10	−6,000	−1
Net loss	−27	−37	−31	−18	−10
Unrealized loss on marketable securities, net	−1,000	—	—	—	—
Net comprehensive loss	−27	−37	—	—	—
Dividend to Series B-1 preferred stockholders	—	−1	−867,000	—	—
Net loss attributable to common stockholders	−27	−38	−31	−18	—
Net loss per share attributable to common stockholders, basic (in Dollars per share)	−1.67	−5.65	−1.28	−1.2	−0.86
Net loss per share attributable to common stockholders, diluted (in Dollars per share)	−1.67	−5.65	−1.28	−1.2	−0.86
Weighted-average shares outstanding used in computing net loss per share, basic (in Shares)	16	7	25	15	12
Weighted-average shares outstanding used in computing net loss per share, diluted (in Shares)	16	7	25	15	12

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	29	26	—	455,000	17
Prepaid expenses and other current assets	8	5	4	2	2
Marketable securities	12	—	—	—	—
Total current assets	49	31	13	3	18
Right of use asset, net	108,000	645,000	766,000	152,000	305,000
Property and equipment, net	66,000	75,000	26,000	22,000	28,000
Total assets	49	32	14	3	19
Accounts payable	383,000	1	839,000	892,000	742,000
Accrued liabilities	2	4	3	2	1
Warrant liability	17	19	13	—	—
Operating lease liability - current	117,000	564,000	327,000	155,000	151,000
Total current liabilities	19	24	18	3	2
Operating lease liability long term	—	117,000	466,000	—	155,000
Total liabilities	19	24	18	3	2
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, value	—	—	—	—	—
Common stock, $0.001 par value per share 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively	22,000	11,000	35,000	15,000	15,000
Accumulated other comprehensive loss	−1,000	—	—	—	—
Additional paid-in capital	158	109	61	34	32
Accumulated deficit	−128	−101	−65	−34	−16
Total stockholders equity	30	7	−4	−466,000	16
Total liabilities and stockholders equity	49	32	14	3	19

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	34,000	22,000	9,000	7,000	1,000
Stock-based compensation expense	3	2	2	1	—
Amortization of operating lease right of use asset	500,000	406,000	275,000	154,000	12,000
Prepaid expense and other current assets	−3	−820,000	−1	62,000	—
Accounts payable and accrued liabilities	−3	790,000	1	1	1
Operating lease liability	−565,000	−397,000	−252,000	−151,000	−12,000
Net cash used in operating activities	−31	−29	−18	−16	−6
Purchases of marketable securities	−12	—	—	—	—
Purchases of property and equipment	−24,000	−72,000	−12,000	−2,000	−29,000
Net cash used in investing activities	−12	−72,000	−12,000	−2,000	−29,000
Gross proceeds from secondary public offering	47	683,000	—	—	—
Commissions paid on secondary public offering	−1	—	—	—	—
Deferred cost of at the market offering	—	−160,000	—	—	—
Payments on financed insurance policies	−212,000	−527,000	−496,000	—	—
Issuance costs related to issuance of Series B-1 preferred stock	—	−4	—	—	—
Proceeds from issuance of Series B-1 preferred stock	—	50	—	—	—
Proceeds from exercise of warrants	1	—	—	—	—
Dividends on preferred stock	—	−1	—	—	—
Net cash provided by financing activities	46	45	28	−471,000	22
Net increase in cash and cash equivalents	3	16	9	−16	—
Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock	—	46	—	—	—
Deferred insurance charges included in prepaid expenses and other current assets	332,000	267,000	270,000	240,000	—
Cash paid for interest	—	12,000	24,000	6,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro